Objectives: The aim of the study is to assess clinical characteristics of individuals with nonsyndromic sensorineural hearing loss (NSSNHL) with genetic mutations in GJB2 and/or GJB6. We describe and compare one group with biallelic mutations against a group of heterozygote mutation carriers.
INTRODUCTION
The diagnosis of DFNB1 depends in the identification of biallelic deafness-causing mutations in GJB2 and/ or GJB6 in subjects with nonsyndromic inherited pattern hearing loss. The vast majority of patients with DFNB1 are either homozygotes or compound heterozygotes with two mutations in GBJ2, the gene that encodes connexin 26. Rarely, patients can have homozygous mutations in GJB6, the gene that encodes for connexin 30 or can carry one mutated allele from each gene in which case they are considered digenic heterozygotes.
Determining the etiology of congenital hearing loss is generally challenging. Risk factors elicited by clinical history and inner ear malformations are some of the ways to determine the cause of a patient's hearing loss. More recently, molecular genetic testing has given clinicians an additional tool in the evaluation of these patients. Screening for mutations in connexin 26 and connexin 30 was previously available at large academic centers. Today, an increasing number of laboratories are offering these tests and it is likely to be offered to many more patients.
Molecular genetic screening for single-gene disorders such as DFNB1 provides a wealth of information. Besides providing a cause for their hearing loss, it can help with prognostication of the course of their disease as well as response to various treatment options. In addition, a patient's parents will better understand the chances of having children with DFNB1, a carrier state, or no mutations at all. The patients themselves will also understand the risks to their children.
As more patients with hearing loss are diagnosed with DFNB1, we are also identifying a group of individuals with hearing loss and only one GJB2 mutation. These DFNB1 carriers pose a diagnostic dilemma. Although these patients can have hearing loss and coincidentally be a carrier of a GJB2 mutation, they can also have hearing loss with DFNB1 secondary to a novel non-GJB2, noncomplementary mutation at the DFNB1 locus. 1 The role of unrecognized mutations is supported by the fact that mutation carrier rates in the general population are lower than the rate of heterozyous GJB2 mutation carriers in the deaf population.
The purpose of this study is to determine the clinical characteristics of DFNB1 carriers presenting with hearing loss and compare them with patients found to have DFNB1. If the groups are overall very different, it would support the notion that these are true DFNB1 carriers with coincidental hearing loss and if the converse were true, it would support the hypothesis of an unrecognized genetic factor contributing to their hearing loss. This information would be helpful to the clinician and patient when molecular genetic testing fails to identify a clear etiology of hearing loss.
MATERIALS AND METHODS

Patient Evaluation
Subjects were recruited from an outpatient otology practice at the University of Miami. A total of 350 patients with nonsyndromic sensorineural hearing loss (NSSNHL) agreed to molecular genetic testing for mutations of GJB2 and GJB6 by giving informed consent. This study was approved by the University of Miami IRB committee, and the recruitment period was between 2002 and 2006.
Each patient underwent a full medical history and physical focusing on their otologic complaints. A questionnaire was completed by the patients or their family at the time of enrollment with specific questions pertaining to their hearing loss, family history, previous radiologic evaluation, and hearing habilitation.
Age-specific pure-tone audiometry was obtained when possible, using equipment in accordance with International Standards Organization (8253-1-3) standards. Pure-tone average (PTA) in decibels (dB) was calculated for each ear by averaging thresholds at three frequencies (0.5, 1, and 2 kHz) in accordance with recommendations of the GENDEAF study group and previous reports from our group. 3, 4 Severity of hearing loss was then categorized as mild (21-40 dB), moderate (41-70 dB), severe (71-95 dB), and profound (95 dB) based on binaural PTA. Asymmetric hearing loss was defined as interaural PTA difference greater than 10 dB in at least two frequencies. Progression of hearing loss was defined as >15 dB loss in binaural PTA within a 10-year period.
Computed tomography (CT) was done with high-resolution 1-mm contiguous axial and coronal images of the temporal bones. When available, images were reviewed by an otologist for inner-ear abnormalities. Otherwise, radiologist reports were reviewed for pertinent findings.
Mutation Screening
All patients were screened for allelic variants in the coding exon (exon 2) of GJB2 using polymerase chain reaction (PCR) amplification. In patients with heterozygous or no mutations in GJB2, further analysis of the noncoding exon (exon 1) was performed using direct sequencing. All patients were also screened for the 342-kb deletion of GJB6 using PCR amplification. DFNB1 was diagnosed if patients had either biallelic pathologic mutations of GJB2, biallelic deletions of GJB6 as described above, or one GJB2 pathologic mutation with the 342-kb deletion of GJB6. Patients with one identified DFNB1-associated mutation were DFNB1 carriers. To rule out a mitochondrial mutation cause of NSSNHL, all patients were also screened for the mitDNA A1555G and A7445G mutations.
Statistical Analysis
Descriptive analysis, one-way ANOVA, and Fisher exact test were used to compare DFNB1 patients and DFNB1 carriers. The level of significance used was P ¼ .05. Statistical calculations were performed using Analyse-It computer software (Analyse-it Software, Ltd., Leeds, UK)
RESULTS
A total of 350 patients were screened for genetic mutations of connexin 26 and connexin 30 after being evaluated for NSSNHL. Thirty-two patients were identified with biallelic pathologic mutations in connexin genes (9.1%). From that cohort, only one patient had homozygous mutations for connexin 30 and two were digenic heterozygotes with mutations in connexin 26 and connexin 30. Twenty-five patients were found to have only one allele pathologic mutation and classified as DFNB1 carriers (7.1%). All of these patients' mutations were in the GJB2 gene. The DFNB1 carrier group had slightly more males (64%) compared with the DFNB1 group (53%), but the difference was not significant (P ¼ .58). The spectrum of mutations for the DFNB1 is shown in Table I and for the DFNB1 carrier group in Table II .
Baseline Hearing Level
Overall the two groups demonstrated a wide range of hearing loss. Binaural pure-tone average levels were calculated from the first complete audiogram. The Mutations were categorized as either protein truncating (nonsense mutations and deletions or insertions leading to frameshifts) or nontruncating (missense mutations). The DFNB1 group was therefore divided into three subgroups: homozygous truncating (81%), homozygous nontruncating (13%), and heterozygous truncating and nontruncating mutations (6%). The DFNB1-carrier group was divided into two subgroups: truncating (56%) or nontruncating (44%). One-way ANOVA was performed to compare the PTA for each group, but the difference only approached significance (P ¼ .054), indicating that no two groups had significantly different means. The largest difference in mean PTA level was between DFNB1 homozygote for truncating mutations and DFNB1 carriers with truncating mutations (34 dB HL). The smallest difference was between the two subgroups of the DFNB1 carrier group (5 dB HL). DFNB1 carriers with truncating mutations had better hearing than those with nontruncating mutations.
Progression of Hearing Loss
Progression of hearing loss could be determined for patients with serial audiograms or if a patient with hearing loss had previously passed their newborn hearing screening test. In the DFNB1 group, four patients had progression of hearing loss documented with serial audiograms and one patient had hearing loss despite passing the newborn hearing screening test. In the DFNB1 carrier group, one patient had progression of hearing loss documented with serial audiograms and one patient had hearing loss despite passing the newborn hearing screening test. This difference in rate of progression of hearing loss between the DFNB1 and DFNB1 carrier groups was not statistically significant (P ¼ .69). Patients found to have progression of hearing loss in the DFNB1 group lost an average of 20 dB HL over an average of 57 months compared with those in the DFNB1 carrier group, who lost an average of 15 dB HL over an average of 42 months.
Incidence of Asymmetry
Asymmetric hearing loss was an uncommon finding in both groups. Five patients with DFNB1 presented with asymmetric hearing loss compared with seven patients who are DFNB1 carriers. There was no statistically significant difference between groups (P ¼ .42).
Radiographic Evaluation
The vast majority of patient underwent radiographic studies to evaluate for inner ear malformations. All patients for which results were available, temporal bone CT was performed except for one patient with DFNB1 who was evaluated with magnetic resonance imaging (MRI) for asymmetric hearing loss. Many patients were initially evaluated with CT imaging and then by MRI as part of the workup preceding cochlear implantation.
Of 27 patients in the DFNB1 group with available radiographic records, three patients had inner ear malformations (11%) including one Mondini malformation, one internal auditory canal with bulbous shape, and one dilated vestibule and lateral semicircular canal. In a similar and nonsignificant (P ¼ 1.0) rate, 1 of 18 patients (6%) in the DFNB1 carrier group had a Mondini inner ear malformation. All abnormalities from both groups were bilateral.
Hearing Habilitation
The majority of patients in this study were referred for a hearing aid evaluation upon diagnosis of hearing loss. One patient from the heterozygous group with mild hearing loss was rehabilitated using an FM system in school. Eventually, a significant number of patients received cochlear implants. In the DFNB1 group, 15 of 26 patients with recorded habilitation method received a cochlear implant (58%) in contrast to 6 of 24 patients (25%) in the DFNB1 carrier group. This difference was statistically significant (P < .05).
DISCUSSION
An evaluation of hearing loss entails a complex workup involving careful histories and physicals, audiologic testing, and radiographic imaging. Molecular genetic testing offers a new tool to determine inherited causes for a patient's hearing loss, and its availability is rapidly growing. There are many reports of the hearing characteristics of patients diagnosed with DFNB1 4,5 but none that focus on hearing-impaired patients who are carriers for DFNB1-related genes. This group presents a complex set of issues because they could be coincidental carriers for the mutation or have an unrecognized second mutated allele at the DFNB1 locus.
In our study, the DFNB1 group had worse hearing loss and underwent treatment with cochlear implantation more frequently. These two variables are surely interrelated because profound hearing loss is an indication for cochlear implantation. This could be attributable to the higher frequency of truncating mutations in the DFNB1 group, which is associated with worse hearing loss. The DFNB1 carrier group was a more heterogeneous cohort in terms of the broader spectrum of degree of hearing loss and proportion of truncating to nontruncating mutations. It is possible that patients from this group with better hearing may indeed be coincidental carriers, while patients with worse hearing may possess an unrecognized mutation. Unfortunately, defining a clear boundary between the two may be difficult because the variation of hearing loss in both groups results in significant overlap.
The remaining variable studies demonstrated remarkable similarity between groups. No differences were noted in the incidence of asymmetry, inner ear radiographic abnormalities, and patients who had progression of their hearing loss. This supports the theory that their hearing loss is of similar etiology.
The conclusions that could be drawn from these results are clinically valuable. Counseling patients with biallelic connexin mutations has been described. No literature outlines how to proceed with counseling of connexin mutation carriers who have hearing loss. Overall, they will have better hearing, end up with cochlear implants less frequently, and rarely have inner ear malformations on imaging. Patients with non-DFNB1-related hearing loss have significantly more inner ear abnormalities than DFNB1 patients. 6 If patients present with better than profound hearing loss, a large proportion can suffer from progression of their hearing loss, making frequent follow-up necessary.
Advising DFNB1 carrier patients regarding the risks to future generations is also important. Patients and their parents must be advised that these screening tests lack 100% sensitivity. If there is indeed an unrecognized mutation responsible, then parents can have a 25% chance of having another hearing-impaired child and the patient's offspring would be obligate carriers. Regardless, the siblings of a DFNB1 carrier should be evaluated for hearing loss to avoid a delay in diagnosis.
Finally, when patients with hearing loss are found to be DFNB1 carriers, they should be considered for DNA banking. DNA extracted from white cells could be stored for future analysis. In situations where the sensitivity of genetic screening is not perfect, these patients may find consolation in the fact that future advances in testing may explain their hearing loss.
CONCLUSIONS
The rapidly expanding use and acceptance of genetic testing for NSSNHL adds a valuable tool to our diagnostic algorithm. Due to the variability of hearing loss, there is no clear and effective way to predict patients who will have DFNB1 and those who will be carriers. However, the similarity of other clinical data suggests that these two groups may share genetic etiologies for their hearing loss. Therefore, it is important to offer molecular genetic screening to all patients with NSSNHL and counsel patients who are DFNB1 carriers about the implications of these tests.
